ImmunoGen seeks conjugate bliss as T-DM1 anticipation builds
This article was originally published in Scrip
After more than 30 years of research that has contributed to the development of its antibody-drug conjugates (ADCs), and with one high-profile oncology candidate on the brink of possible US FDA approval, ImmunoGen is advancing its first wholly-owned ADCs developed with the company's Targeted Antibody Payload (TAP) technology into mid-stage development.
You may also be interested in...
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.